Brief: Kancera Reports Positive Top-Line Results From Kandova Study

Novakand Pharma AB

13/06/2025 07:09

June 13 (Reuters) - Kancera AB KANC.ST:

REPORTS POSITIVE TOP-LINE RESULTS FROM KANDOVA STUDY

PRIMARY OBJECTIVE WAS MET - TO DETERMINE RECOMMENDED DOSE AND EVALUATE SAFETY AND TOLERABILITY

SECONDARY OBJECTIVE - TO SHOW SIGNALS OF KAND567'S ANTI-TUMOR EFFECT IN COMBINATION WITH CARBOPLATIN, WAS ALSO MET

73% PATIENTS SHOW PARTIAL RESPONSE OR STABLE DISEASE AT WEEK 12

Source text: ID:nMFNbZwkbv

Further company coverage: KANC.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))